Vega CR, Vega YIO, Vega JJ, Milián MS

Language: Spanish
References: 14
Page: 118-123
PDF size: 229.56 Kb.

Text Extraction

To the Editor:

It is with concern and regrettable foresight that I turn to you, seeing that the comorbidity of obese patients is becoming an epidemic. It is no longer only obesity that is of concern, but also the changes of all kinds that take place in organ structure and function –including the cell that pose a great danger to the heart and life.
In an article referring to coronary microcirculation and the clinical-epidemiological variables found in 117 diabetic patients with myocardial infarction and normal coronary arteries, a significant prevalence of overweight (19.7%) and obesity (80.3%) was observed. This takes place despite the new drugs available for glycemic control and the maintenance of acceptable, even normal, glycosylated hemoglobin parameters. The sodium-glucose cotransporter-2 (SGLT-2) inhibitors, empagliflozin and canagliflozin and the GLP-1 (glucagon-like peptide-1) receptor agonists, liraglutide and semaglutide; have decreased the risk of cardiovascular death, myocardial infarction and stroke, once they were added to the therapeutic protocols for patients with type 2 diabetes mellitus. Many of these patients have overweight or obesity, which multiplies their risk of complications and adverse events during their lifetime.

REFERENCES

1. Vega Candelario R. Variables clinicoepidemiológicas, microcirculación coronaria [Internet]. ResearchGate [citado 11 Mar 2020];2020. Disponible en: https://www.researchgate.net/publication/338990076_Variables_clinicoepidemiologicas_microcirculacion_coronaria

2. Matta-Herrera GJ, Ballestas-Alarcón LM, Ramírez-Rincón A. Agonistas de GLP-1 más inhibidores de SGLT2. ¿Efectos cardioprotectores aditivos? Med Int Méx. 2018;34(4):601-13.

3. Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(3):709-57. DOI: https://doi.org/10.1210/jc.2016-2573

4. Gil-Ortega M, Martín-Ramos M, Arribas SM, González MC, Aránguez I, Ruiz-Gayo M, et al. Arterial stiffness is associated with adipokine dysregulation in non-hypertensive obese mice. Vascul Pharmacol. 2016;77:38-47. DOI: https://doi.org/10.1016/j.vph.2015.05.012

5. Ortega FB, Sui X, Lavie CJ, Blair SN. Body mass index, the most widely used but also widely criticized index: Would a criterion standard measure of total body fat be a better predictor of cardiovascular disease mortality? Mayo Clin Proc. 2016;91(4):443-55. DOI: https://doi.org/10.1016/j.mayocp.2016.01.008

6. Gil-Ortega M, Condezo-Hoyos L, García-Prieto CF, Arribas SM, González MC, Aranguez I, et al. Imbalance between pro and anti-oxidant mechanisms in perivascular adipose tissue aggravates long-term high-fat diet-derived endothelial dysfunction. PLoS One [Internet]. 2014 [citado 16 Mar 2020];9(4):e95312. Disponible en: https://doi.org/10.1371/journal.pone.0095312

7. Gil-Ortega M, Fernández-Alfonso MS, Somoza B, Casteilla L, Sengenès C. Ex vivo microperfusion system of the adipose organ: A new approach to studying the mobilization of adipose cell populations. Int J Obes (Lond). 2014;38(9):1255-62. DOI: https://doi.org/10.1038/ijo.2013.243

8. Blancas-Flores G, Almanza-Pérez JC, López-Roa RI, Alarcón-Aguilar FJ, García-Macedo R, Cruz M. La obesidad como un proceso inflamatorio. Bol Med Hosp Infant Mex. 2010;67(2):88-97.

9. Flores-Lázaro JR, Rodríguez-Martínez E, Rivas-Arancibia S. Consecuencias metabólicas de la alteración funcional del tejido adiposo en el paciente con obesidad. Rev Med Hosp Gen Méx. 2011;74(3):157-65.

10. Suárez-Carmona W, Sánchez-Oliver AJ, González-Jurado JA. Fisiopatología de la obesidad: Perspectiva actual. Rev Chil Nutr. 2017;44(3):226-33. DOI: http://dx.doi.org/10.4067/s0717-75182017000300226

11. Rodríguez A, Ezquerro S, Méndez-Giménez L, Becerril S, Frühbeck G. Revisiting the adipocyte: a model for integration of cytokine signaling in the regulation of energy metabolism. Am J Physiol Endocrinol Metab. 2015;309(8):E691-714. DOI: https://doi.org/10.1152/ajpendo.00297.2015

12. Moreno-Martínez FL. Obesidad y distribución regional de la grasa: Viejos temas con nuevas reflexiones. CorSalud [Internet]. 2011 [citado 20 Mar 2020];3(1). Disponible en: http://www.corsalud.sld.cu/sumario/2011/v3n1a11/distribucion.htm

13. Ortega FB, Lavie CJ, Blair SN. Obesity and Cardiovascular Disease. Circ Res. 2016;118(11):1752-70. DOI: https://doi.org/10.1161/circresaha.115.306883

14. Ochoa Montes LA, González Lugo M, Vilches Izquierdo E, Fernández-Britto Rodríguez JE, Araujo González RE; Sección de Investigación en Muerte Súbita de la Sociedad Cubana de Aterosclerosis. Muerte súbita cardiovascular en poblaciones de riesgo. CorSalud [Internet]. 2014 [citado 21 Mar 2020];6(Supl 1):71-8. Disponible en: http://www.corsalud.sld.cu/suplementos/2014/v6s1a14/pob-riesgo.html